Navigation Links
MEI Pharma To Host Annual Meeting Of Stockholders
Date:3/20/2013

SAN DIEGO, March 20, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, will host its Annual Meeting of Stockholders at 10:00 a.m. Pacific time on Tuesday, March 26, 2013 at the offices of Morgan, Lewis & Bockius LLP, located at One Market, Spear Street Tower in San Francisco, to consider and vote on certain matters, including the election of a director, the ratification of the appointment of the Company's independent registered public accounting firm, the approval of the amendment and restatement of the Company's certificate of incorporation, and the approval of the amendment and restatement of the Company's equity compensation plan. A live webcast of the meeting will be accessible at www.meipharma.com/investor. A replay will be available approximately one hour after the presentation.

(Logo: http://photos.prnewswire.com/prnh/20120628/LA32362LOGO)

About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's lead drug candidate is Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor being developed for advanced hematologic malignancies such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Results from a pilot Phase II clinical trial of Pracinostat in combination with azacitidine in patients with advanced MDS were presented at the American Society of Hematology Annual Meeting in December 2012 showing an overall response rate (CR+CRi+PR) of 89% (eight out of nine). The Company plans to initiate a randomized, placebo-controlled Phase II trial of Pracinostat in combination with azacitidine in patients with MDS in June 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. For more information, go to www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.


'/>"/>
SOURCE MEI Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PQA and CECity Launch Joint Venture to Deliver First National Pharmacy Quality Measurement, Benchmarking and Reporting Platform for Pharmacies and Health Plans
2. First Patients Dosed in Proof-of-Concept Clinical Study of Alder Biopharmaceuticals Lead Therapeutic Candidate for Treatment of Migraine, ALD403
3. Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash
4. Tech Coast Angels Contributes More Than $3 Million to $16 Million Savara Pharmaceuticals Series B
5. Financial Assessment of the Global Pharmaceutical and Biotechnology Industry
6. Harwood Feffer LLP Announces Investigation of Spectrum Pharmaceuticals, Inc.
7. Plato BioPharma Presenting Preclinical capabilities at PKPD Summit Boston
8. National Pharmaceutical Council Survey Shows Health Care Stakeholders Continue to Show Optimism About the Future Role of Comparative Effectiveness Research
9. Pharmaceutical Distribution Agreement Between Cardinal Health And Walgreens To End August 2013
10. Star Scientific and Rock Creek Pharmaceuticals Report on the Beneficial Nutritional Effects of Anatabine in an Animal Model of Ulcerative Colitis
11. Research-based Pharmaceutical Industry and International Federation of Red Cross and Red Crescent Societies Join Forces to Prevent Non-Communicable Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... -- From the company that brought a full line of equine first ... new line of companion animal pet first aid kits.  EquiMedic ... aid, has developed two sizes of small pet first aid kits ... Featuring a small and a large companion pet first aid ... not a newcomer to working with small animals either. Corporate owners, ...
(Date:1/17/2017)... 17, 2017  OrthoAccel ® Technologies, Inc. announces ... has published "The Effect of Vibration on Molar Distalization," ... Dr. S. Jay Bowman , this prospective, peer-reviewed ... AcceleDent,s SoftPulse Technology ® speeds up molar distalization ... the number of days to move the upper molars ...
(Date:1/17/2017)... Research and Markets has announced the addition ... report to their offering. ... The global fluoropolymer market in the healthcare industry to ... Global Fluoropolymer Market in the Healthcare Industry 2016-2020, has ... industry experts. The report covers the market landscape and its growth ...
Breaking Medicine Technology:
(Date:1/17/2017)... New York, NY (PRWEB) , ... January 17, 2017 , ... ... the grand opening of a new showroom at South Dixie Hwy in Miami, FL. ... Marketing Officer at Gym Source. “The new innovative in-store concept is designed to give ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... by the political/social/economic events, Dr. Carol Francis re-releases powerfully uplifting interview with medical ... moments that help everyone endure and pass through tough times, Dr. Bernie Siegel ...
(Date:1/17/2017)... ... January 17, 2017 , ... Kevin Harrington (one of the original ... featuring DRTV campaigns regarding the topic of Beauty and Personal Care. ... themselves. What better way to commit to these changes than beginning with personal care ...
(Date:1/17/2017)... ... January 17, 2017 , ... Achieve TMS ... is opening a new office in San Clemente, California this month. Achieve TMS ... Southern California, successfully treating individuals struggling with major depression. Depression impacts over 15 ...
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples ... the Peoples Health network on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare ... Center is an exciting addition to our provider network, and the addition will ...
Breaking Medicine News(10 mins):